This listing has debuted. The live 5-factor QL signal switches on as soon as the engine has enough trading history.
We are a clinical-stage biotechnology company engineering purpose-built in vivo CRISPR technologies designed to extend healthy lifespan through disease prevention and durable therapeutic intervention. While current genetic medicines are largely limited to rare disorders, we are engineering our technologies for use in common diseases affecting millions.
From Scribe Therapeutics Inc.'s Form 424B4 filed with the SEC on 2026-07-27. The issuer's own words — QuantLogix does not paraphrase it.
| Net loss | $21,800,000 | year ended December 31, 2025vs $47,800,000 · year ended December 31, 2024 | -54.4% |
|---|
Figures as stated in the prospectus, not QuantLogix estimates. From Scribe Therapeutics Inc.'s Form 424B4 filed with the SEC on 2026-07-27.
From Scribe Therapeutics Inc.'s Form 424B4 filed with the SEC on 2026-07-27. Extraction is deterministic — the same filing always produces the same score; 730k characters of the document were scanned. Technology signals are lexical indicators, not a technical audit. Not investment advice; the debut itself will be this score's first grade.
Deal terms come from the public IPO calendar and change up to pricing — an expected date reads “to be announced” until the underwriters set it, and a range is not a final price. Implied market cap and float are arithmetic on those disclosed terms. Nothing on this page is a forecast or a recommendation.